Company Filing History:
Years Active: 2015-2017
Title: Sandra Bruder: Innovator in Prolactin Receptor Antibodies
Introduction
Sandra Bruder is a notable inventor based in Leverkusen, Germany. She has made significant contributions to the field of biomedicine, particularly in the development of neutralizing prolactin receptor antibodies. With a total of 3 patents to her name, her work has the potential to impact various therapeutic areas.
Latest Patents
Sandra Bruder's latest patents focus on neutralizing prolactin receptor antibodies and their therapeutic applications. The first patent describes the neutralizing prolactin receptor antibody 006-H08, along with its maturated forms and antigen-binding fragments. This invention aims to treat or prevent benign disorders mediated by the prolactin receptor, including endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease, mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, and hair loss. The antibodies developed in this patent effectively block prolactin receptor-mediated signaling. The second patent similarly addresses the neutralizing prolactin receptor antibody 005-C04, detailing its therapeutic uses in the same range of benign disorders.
Career Highlights
Throughout her career, Sandra Bruder has worked with prominent companies in the biotechnology sector. She has been associated with Bayer Intellectual Property GmbH and Seattle Genetics, Inc., where she has contributed her expertise in antibody development and therapeutic applications.
Collaborations
Sandra has collaborated with notable colleagues, including Simone Greven and Axel Harrenga, enhancing her research and development efforts in the field.
Conclusion
Sandra Bruder's innovative work in the development of prolactin receptor antibodies showcases her commitment to advancing medical science. Her patents hold promise for improving treatment options for various benign disorders, reflecting her significant impact in the field of biomedicine.